This seminar series will be discussing issues of generalizability, transportability, and representation in Alzheimer’s disease (AD) diagnosis and clinical trials. We will be considering the role of AD biomarkers and other eligibility criteria in determining who enters the clinical trials and cohort studies on which we base our conclusions and clinical recommendations.
Ian Troidl Co-Authors New Study in JAMA Internal Medicine
Exciting new research from our team published in JAMA Internal Medicine! A recently published study titled "Homicide Risk During 10-Day Waiting Period Among First-Time Handgun Purchasers in California" of over 1 million first-time handgun purchasers in California...








